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Abstract. Background/Aim: In breast cancer (BC) patients,
breast surgery followed by immediate breast reconstruction
(IBR) might favour recurrences and metastases due to
extensive surgical manipulation. We retrospectively
investigated whether IBR after mastectomy and neoadjuvant
chemotherapy (NT) influenced the outcome in patients with
early and locally advanced oestrogen receptor (ER)-negative
BC. Patients and Methods: Between 1995 and 2006, 133 BC
patients received NT followed by total mastectomy, 59 of
whom underwent IBR. Patients receiving IBR (IBR group)
were compared to patients who did not receive IBR (no-IBR
group) over a prolonged median follow-up time (8.2 years).
Results: Patients receiving IBR were on average younger
than patients not receiving IBR (p<0.001). The percentage
of patients with positive clinical nodal status (cN) was 19%
in the IBR group and 7% in no-IBR group (p=0.036),
whereas patients without IBR were more frequently
diagnosed as clinical T4 (59% vs. 15%, p<0.001). The 5-
year cumulative incidence of locoregional recurrences were
14% in the no-IBR group and 21% in the IBR group. The
hazard of locoregional events, adjusted for age, clinical T
and cN, was significantly greater in the IBR group than in
the no-IBR group (hazard ratio (HR)=2.77, p=0.045). The
5-year cumulative incidences of distant metastases were
similar in the two groups (p=0.414). Conclusion: IBR
following total mastectomy in patients with ER-negative
disease after NT is associated with a worse rate of local
relapses. More insight in mechanisms of wound healing and
extent of surgery is required to further investigate this
observation.
Mastectomy with immediate breast reconstruction (IBR) is a
treatment option for patients with breast cancer (BC) when
breast-conserving surgery is not feasible.
IBR has been associated with patient satisfaction (1, 2),
improvement in quality of life (3) and no detrimental effect
on survival outcomes (4).
As yet, very few data have been published upon IBR in
BC patients treated with neoadjuvant chemotherapy (NT)
(5), especially for restricted to hormone receptor negative
tumors and within studies with biologically heterogeneous
populations.
Evidence suggests that extended breast surgery may
induce stimulation of residual cancer cells through
angiogenic cytokine release (6, 7).
We hypothesized that breast surgery followed by IBR
might further stimulate abnormal cell proliferation through
growth factor release due to extensive surgical manipulation,
compared to total mastectomy-alone. This effect might be
more striking in a sub-population with endocrine non-
responsive disease. Moreover the possible correlation with
NT has never been widely investigated.
In the present study, non-endocrine responsive BC patients
were submitted to IBR after total mastectomy and NT, and
were compared to patients who did not receive IBR (control
group) retrospectively to assess locoregional recurrence,
distant metastases and survival outcomes.
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Patients and Methods
Patients, inclusion criteria and treatment approaches. From 1995 to
2006, at the European Institute of Oncology, Milan, a total of 133
non-endocrine responsive BC patients received NT (taxanes plus
anthracyclines alone), total mastectomy and complete axillary
dissection. Fifty-nine patients of the whole cohort were submitted
to IBR, 28 with prosthesis, 27 with expander (after removal, 13
were submitted to reconstruction with prosthesis, one with
transverse rectus abdominus myocutaneous (TRAM) flap; no data
were available for 13 patients) and 4 immediately with TRAM flap
reconstruction, respectively.
Only patients with invasive BC hormone receptor-negative
underwent mastectomy after NT were eligible for analysis; no
previous diagnosis of BC was permitted. Patients with distant
metastases and supraclavicular lymph nodes were not eligible and
patients with inflammatory BC were excluded. Eligible patients
were those who could receive contralateral reduction mastoplasty
and mastopexy.
Indication for IBR was planned on a case by case basis during a
weekly multidisciplinary panel of experts, including oncologists,
radiologists, cytopathologists, surgeons and reconstructive surgeons;
guidelines for IBR after neoadjuvant therapy did not exist. Patient
preference, panel opinion and the cosmetic outcome were carefully
taken into consideration; in our Institute the reconstructive
procedure is discussed as routine within BC treatment. Clinical
tumor size and nodal status (cN) were the categories basically
assessed to select or not patients for IBR. Tumors less than or equal
to T3 and negative cN were preferred. Systemic treatments and
human epidermal growth factor receptor 2 (HER2) status did not
hamper the decision process for IBR.
The indication for adjuvant radiotherapy was based on lymph
node status and tumor size, both assessed pre- and post-mastectomy.
IBR did not represent a contraindication for subsequent
radiotherapy, however high risk of capsular contracture existed and
flap reconstructions were usually preferred when RT was indicated.
Concerning chemotherapy as adjuvant, metronomic
cyclophosphamide (50 mg per os (p.o.) daily) and methotrexate 
(2.5 mg p.o.) twice daily on day 1 and day 4 weekly) were given.
All patients were followed every six months with clinical and
radiological controls. Mammography on the contralateral breast was
performed every year, bilateral breast ultrasound every six months,
liver ultrasound every year and biological markers every six months.
Statistical methods. Differences in the distribution of subject
characteristics between groups were evaluated by the Chi-square test.
The endpoints evaluated were disease-free survival (DFS), overall
survival (OS), cumulative incidence of local or regional recurrence
(CI-LR) and distant metastases (CI-DM). 
DFS was defined as the time from surgery to events such as
relapse (including ipsilateral breast recurrence), appearance of a
second primary cancer (including contralateral breast cancer) or
death, whichever occurred first. OS was defined as the time from
surgery until the date of death (from any cause). The DFS and OS
functions were estimated using the Kaplan–Meier method. The CI-
LR and CI-DM were defined as the time from the date of surgery to
a local or regional recurrence and a distant metastasis, respectively.
The CI-LR and CI-DM functions were estimated according to
methods described by Kalbfleisch and Prentice (8), taking into
account the competing causes of recurrence.
The prognostic impacts of IBR on DFS, OS, cumulative
incidence of locoregional recurrence and cumulative incidence of
distant metastases were estimated by the multivariable Cox
proportional hazards regression model, controlled for age at
diagnosis, clinical tumor size (cT) and cN. Model-based hazard
ratios (HR) with 95% confidence intervals (CI) were presented. 
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Table I. Demographic, clinical and pathological characteristics and
local and systemic treatments of the 133 patients, categorized as either
not receiving or receiving an immediate breast reconstruction (IBR).
Without IBR With IBR p-Value*
(N=74) (N=59)
N (%) N (%)
Age class (years)
<35 3 (4) 19 (32) <0.001
35-49 25 (34) 28 (48)
50-59 34 (46) 9 (15)
60-69 9 (12) 2 (3)
70+ 3 (4) 1 (2)
Menopausal status
Pre-menopausal 28 (38) 40 (68) <0.001
Post-menopausal 46 (62) 19 (32)
Histotype
Ductal 65 (88) 56 (95) 0.197
Lobular 4 (5) 1 (2)
Other 5 (7) 2 (3)
Multicentric/Multifocal
No 55 (74) 48 (81) 0.335
Yes 19 (26) 11 (19)
Clinical nodal status
Unknown 12 (16) 9 (15) 0.036
Negative 57 (77) 39 (66)
Positive 5 (7) 11 (19)
Clinical T
Unknown 2 (3) 6 (10) <0.001
T1-T2 11 (15) 22 (37)
T3 17 (23) 22 (37)
T4 44 (59) 9 (15)
Perivascular invasion
Absent 33 (45) 26 (44) 0.417
Focal 12 (16) 11 (19)
Moderate 8 (11) 2 (3)
Extensive 21 (28) 20 (34)
HER2 overexpressed
Unknown 10 (13) 9 (15) 0.334
Intense and complete 34 (46) 22 (37)
Not Expressed 30 (41) 28 (48)
KI-67
Unknown 5 (7) 1 (2) 0.402
<14% 12 (16) 7 (12)
>=14% 57 (77) 51 (86)
Adjuvant local and 
systemic treatment
Radiotherapy 53 (72) 21 (36) <0.001
Chemotherapy 70 (95) 54 (91) 0.483
Trastuzumab 7 (9) 7 (12) 0.653
*Unknown are not considered in the p-value calculation. 
The analyses were carried-out with the SAS software (SAS
Institute, Cary, NC, USA). All reported p-values are two-sided.
Results
Demographic, clinical and pathological characteristics and
local and systemic treatments of the 133 patients are shown
in Table I, categorized as either receiving (N=59) or not
(N=74) IBR.
No significant differences between the IBR group and no-
IBR group could be found in terms of histologic type, presence
of multicentric/multifocal lesions, perivascular invasion, HER2
overexpression and Ki-67 score. Patients receiving IBR were
on average significantly younger than patients not receiving
IBR (p<0.001). Accordingly, menopausal status was
significantly associated. The percentage of patients with
positive cN was higher in the IBR group (7% in the no IBR
group vs. 19% in IBR group, p=0.036), while patients without
IBR were more frequently diagnosed as clinical T4 (59% in the
no IBR group vs. 15% in IBR group, p<0.001).
Fifty-three patients in the no-IBR group (72%) and 21
patients in the IBR group (36%) received radiotherapy
(p<0.001); 70 (95%) and 54 (91%) received chemotherapy
in the no-IBR and IBR group, respectively (p=0.483). Only
7 patients (9%) and 7 patients (12%) received trastuzumab
in the no IBR and IBR group, respectively (p=0.653). 
Two patients with pathological complete response to NT
were observed in the IBR group (2%) vs. none in the no-IBR
group. Twenty-six (44%) partial responses were observed in
the IBR group vs. 30 (41%) in the no-IBR group. The
difference in response rates between the two groups was not
statistically significant (p=0.236).
After a median follow-up of 8.2 years, 53 (72%) and 43
(73%) first events were observed in the no-IBR group (10
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Figure 1. Overall survival, by IBR status. Hazard ratio (HR), 95% confidence interval (CI) and p-value, adjusted for age, cT and cN, are reported.
local and regional events, 33 distant metastases and 10 other
events) and the IBR group (13 local and regional events, 27
distant metastases and 3 other events), respectively. Forty-
four (59%) and 35 (59%) patients died during the follow-up
in the no-IBR group and the IBR group respectively.
The Kaplan–Meier curves for OS and DFS and the
cumulative incidence of locoregional recurrences and distant
metastases, according to IBR status, are displayed in Figures
1 to 4. HR estimated from multivariable analyses, adjusted
for age, cT and cN, are also presented.
The 5-year OS proportions were 48% (95%CI=36%-59%)
in the no-IBR group and 55% (95%CI=41%-67%) in the
IBR group (Figure 1). The 5-year DFS proportions were
32% (95%CI=22%-43%) in the no IBR group and 32%
(95%CI=20%-44%) in the IBR group (Figure 2). The
estimated hazards of death and of first event were greater in
the IBR group than in the no IBR group (HR for death=1.32
and HR for first event=1.42) but they were not statistically
significant (p=0.303 for OS and p=0.156 for DFS).
The 5-year cumulative incidences of local or regional
recurrences were 14% (95%CI: 6%-22%) in the no-IBR
group and 21% (95%CI=10%-31%) in the IBR group
(Figure 3). The estimated hazard of loco-regional event was
significantly greater in the IBR group than in the no-IBR
group (HR=2.77, p=0.045). The observed difference between
the two incidence curves was mainly due to an increase of
early local and regional relapses (i.e. observed within two
years after surgery) in the IBR group.
The 5-year cumulative incidences of distant metastases
were 42% (95%CI: 31%-53%) in the no-IBR group and 46%
(95%CI=32%-59%) in the IBR group (Figure 4). The
estimated hazard of distant metastases was not significantly
greater in the IBR group than in the no IBR group (HR=1.29,
p=0.414).
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Figure 2. Disease-free survival, by IBR status. Hazard ratio (HR), 95% confidence interval (CI) and p-value, adjusted for age, cT and cN, are
reported.
Although not significant, the use of radiotherapy did not
seem to improve the non-favorable trend for the IBR group
(Figure 5).
Discussion
In our series of 133 BC patients submitted to total
mastectomy after NT, 59 of whom underwent IBR, the
reconstructive procedure seems to be associated to a worse
rate of locoregional recurrences with borderline significance,
while significantly negative conclusions with regard to
survival outcomes were not observed.
To our knowledge, this is the largest published series
addressing the role of IBR after preoperative treatment, no
previous study in patients with and without IBR has explored
such topic in ER negative tumors.
Extensive surgical manipulation (mastectomy plus IBR)
might be theoretically disadvantageous as hypothesized
above, certainly tumor biology is not a secondary concern. To
this end, Kneubil et al. assessed the incidence of locoregional
recurrence in a large series of consecutive BC patients
according to pathological features and demonstrated higher
5-year cumulative incidence of locoregional recurrence (11%)
for triple-negative tumors (ER negative, progesterone receptor
(PgR)-negative and HER2-negative) (9). In our analysis
nearly two-thirds of the study population was triple-negative.
Interestingly, the incidence rate of loco-regional
recurrence was greater in patients with IBR than in patients
without IBR within the first two years after reconstruction,
while remained similar among the two groups afterwards
(Figure 3). This observation is in agreement with the
difference, slightly in favour, of the group without IBR we
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Figure 3. Cumulative incidence of local and regional recurrence, by IBR status. Hazard ratio (HR), 95% confidence interval (CI) and p-value,
adjusted for age, cT and cN, are reported.
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Figure 4. Cumulative incidence of distant metastasis, by IBR status. Hazard ratio (HR), 95% confidence interval (CI) and p-value, adjusted for age,
cT and cN, are reported.
Figure 5. Cumulative incidence of locoregional recurrence: stratified analysis for radiotherapy.
observe in DFS (Figure 2). Furthermore, these data are in
line with Sandelin et al. (10) who documented that most
recurrences occurred within 24 months after IBR.
Of interest, the cumulative incidence of distant metastases
between the two groups (Figure 4) was higher for the IBR
group after 5 years and the difference was steadily retained
until 8 years after reconstruction; however, without any
statistical significance.
Intriguingly, the clinical response to intravenous
chemotherapy as neoadjuvant did not influence the decision
of performing IBR, since both groups did not show
meaningful differences in response rates.
The impact of radiotherapy on IBR is still a controversial
issue. Evidence supports the treatment with a breast
prosthesis without affecting the dosage schedule and/or
increased morbidity (11, 12). In our analysis, one third of the
IBR group patients received radiation therapy implying that
the higher cumulative incidence of locoregional events in the
IBR group is likely due to the low dosages received.
Therefore, we believe that patient selection for IBR is crucial
and cT, for instance, must be previously carefully evaluated.
The reconstructive surgeon should confer with others team
members a treatment suitable for the stage of cancer and
other characteristics at diagnosis.
One of the strengths of our study is the long follow-up
time with a median of 8.2 years and the biologically-
homogenous series, referring to hormone receptor negative
status. Conversely, the retrospective nature of such study, the
two not well-matched groups and the lack of data of final
reconstruction for 13 patients are intrinsic drawbacks. The
unbalanced indication of radiotherapy in the two groups
(knowing the role of radiotherapy to decrease the risk of LR)
has also to be considered.
The potential advantages and disadvantages of IBR and
the optimal timing and method of radiation could be better
assessed in prospective studies; however, a retrospective
controlled study, such as the one presented in this paper,
based on data collected on all patients consecutively operated
in a single institution and where all patients were actively
followed-up, could yield useful and reliable prognostic
information in breast cancer patients who underwent IBR.
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